These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38898304)

  • 1. Application of the Finite Absorption Time (F.A.T.) Concept in the Assessment of Bioequivalence.
    Tsekouras AA; Macheras P
    Pharm Res; 2024 Jul; 41(7):1413-1425. PubMed ID: 38898304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revising Pharmacokinetics of Oral Drug Absorption: II Bioavailability-Bioequivalence Considerations.
    Chryssafidis P; Tsekouras AA; Macheras P
    Pharm Res; 2021 Aug; 38(8):1345-1356. PubMed ID: 34341958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revamping Biopharmaceutics-Pharmacokinetics with Scientific and Regulatory Implications for Oral Drug Absorption.
    Alimpertis N; Tsekouras AA; Macheras P
    Pharm Res; 2023 Sep; 40(9):2167-2175. PubMed ID: 37537424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitivity of indirect metrics for assessing "rate" in bioequivalence studies--moving the "goalposts" or changing the "game".
    Rostami-Hodjegan A; Jackson PR; Tucker GT
    J Pharm Sci; 1994 Nov; 83(11):1554-7. PubMed ID: 7891273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Examining the role of metabolites in bioequivalence assessment.
    Karalis V; Macheras P
    J Pharm Pharm Sci; 2010; 13(2):198-217. PubMed ID: 20816006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of metabolites in bioequivalency assessment. III. Highly variable drugs with linear kinetics and first-pass effect.
    Jackson AJ
    Pharm Res; 2000 Nov; 17(11):1432-6. PubMed ID: 11205739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absorption rate vs. exposure: which is more useful for bioequivalence testing?
    Tozer TN; Bois FY; Hauck WW; Chen ML; Williams RL
    Pharm Res; 1996 Mar; 13(3):453-6. PubMed ID: 8692741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Columbus' egg: Oral drugs are absorbed in finite time.
    Macheras P; Tsekouras AA
    Eur J Pharm Sci; 2022 Sep; 176():106265. PubMed ID: 35863551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PBPK Absorption Modeling of Food Effect and Bioequivalence in Fed State for Two Formulations with Crystalline and Amorphous Forms of BCS 2 Class Drug in Generic Drug Development.
    Rebeka J; Jerneja O; Igor L; Boštjan P; Aleksander B; Simon Ž; Albin K
    AAPS PharmSciTech; 2019 Jan; 20(2):59. PubMed ID: 30623248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Theoretical Investigation of Dissolution Test Criteria for Waiver of Clinical Bioequivalence Study.
    Sugano K
    J Pharm Sci; 2016 Jun; 105(6):1947-1951. PubMed ID: 27238491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiologically Based Pharmacokinetic Modeling of Oral Absorption, pH, and Food Effect in Healthy Volunteers to Drive Alpelisib Formulation Selection.
    Gajewska M; Blumenstein L; Kourentas A; Mueller-Zsigmondy M; Lorenzo S; Sinn A; Velinova M; Heimbach T
    AAPS J; 2020 Oct; 22(6):134. PubMed ID: 33070288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologically based absorption modeling to predict bioequivalence of controlled release and immediate release oral products.
    Mitra A; Petek B; Bajc A; Velagapudi R; Legen I
    Eur J Pharm Biopharm; 2019 Jan; 134():117-125. PubMed ID: 30472143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IVIVC Revised.
    Alimpertis N; Simitopoulos A; Tsekouras AA; Macheras P
    Pharm Res; 2024 Feb; 41(2):235-246. PubMed ID: 38191705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity of empirical metrics of rate of absorption in bioequivalence studies.
    Ring A; Tothfalusi L; Endrenyi L; Weiss M
    Pharm Res; 2000 May; 17(5):583-8. PubMed ID: 10888310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DeMonS--a new deconvolution method for estimating drug absorbed at different time intervals and/or drug disposition model parameters using a monotonic cubic spline.
    Yu Z; Hwang SS; Gupta SK
    Biopharm Drug Dispos; 1997 Aug; 18(6):475-87. PubMed ID: 9267681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Simulation Study of the Comparative Performance of Partial Area under the Curve (pAUC) and Partial Area under the Effect Curve (pAUEC) Metrics in Crossover Versus Replicated Crossover Bioequivalence Studies for Concerta and Ritalin LA.
    Jackson AJ; Foehl HC
    AAPS J; 2022 Jul; 24(4):80. PubMed ID: 35798921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cutoff time point of the partial area method for assessment of rate of absorption in bioequivalence studies.
    Macheras P; Symillides M; Reppas C
    Pharm Res; 1994 Jun; 11(6):831-4. PubMed ID: 7937521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanistic Oral Absorption Modeling and Simulation for Formulation Development and Bioequivalence Evaluation: Report of an FDA Public Workshop.
    Zhang X; Duan J; Kesisoglou F; Novakovic J; Amidon GL; Jamei M; Lukacova V; Eissing T; Tsakalozou E; Zhao L; Lionberger R
    CPT Pharmacometrics Syst Pharmacol; 2017 Aug; 6(8):492-495. PubMed ID: 28571121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.